Selected article for: "acute respiratory syndrome coronavirus and additional treatment"
Author: Koehler, Johanna; Ritzer, Barbara; Weidlich, Simon; Gebhardt, Friedemann; Kirchhoff, Chlodwig; Gempt, Jens; Querbach, Christiane; Hoffmann, Dieter; Haller, Bernhard; Schmid, Roland M.; Schneider, Jochen; Spinner, Christoph D.; Iakoubov, Roman
Title: Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
  • Cord-id: uctzyltn
  • Document date: 2021_7_9
    • ID: uctzyltn
    Snippet: Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results
    Document: Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s15010-021-01657-y.

    Search related documents:
    Co phrase search for related documents
    • active cancer and admission day: 1
    • active cancer and local ethic committee: 1
    • active cancer and low number: 1, 2, 3
    • active cancer and lung disease: 1, 2, 3, 4
    • acute respiratory syndrome and additional analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory syndrome and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and local ethic committee: 1
    • acute respiratory syndrome and low number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and mab administration: 1, 2
    • additional analysis and admission day: 1
    • additional analysis and low number: 1, 2
    • additional analysis and lung disease: 1, 2
    • admission day and low number: 1
    • admission day and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • low number and lung disease: 1, 2, 3, 4